Lava Liquid Embolic System (Lava LES) and Lava Mixing Kit
Sirtex Medical, Inc. · Decision date Sep 3, 2025
What did the FDA approve?
FDA records P220020/S005 as a supplement to PMA P220020, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Sep 3, 2025.
FDA approval order statement
Approval for a contract manufacturing site located in Wilmington, Massachusetts and to change the legal manufacturer address
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 3, 2025
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P220020/S005
- Regulatory pathway
- PMA supplement
- Applicant
- Sirtex Medical, Inc.
- Product code
- QVG
- Decision code
- APPR
- Decision date
- Sep 3, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Embolization Agent, Vascular.
- Applicant
- Sirtex Medical, Inc.
- Product code
- QVG
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P220020/S005 received
Application receipt date recorded by FDA.
P220020/S007 · Related supplement
Lava Liquid Embolic System (Lava LES) and Lava Mixing Kit
P220020/S005 · FDA decision
Normal 180 Day Track No User Fee
P220020/S008 · Related supplement
Lava Liquid Embolic System (Lava LES)
Timeline entries are records held by MedtechLedger for P220020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Sirtex Medical, Inc. | PMA supplement | Aug 5, 2025 | FDA | |
Lava Liquid Embolic System (Lava LES)P220020/S008 | Sirtex Medical, Inc. | PMA supplement | Jul 9, 2026 | FDA |
Explore the linked device profile
Other records with product code QVG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Embrace(TM) Hydrogel Embolic SystemP250003/S008 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Embrace Hydrogel Embolic SystemP250003/S011 | Instylla, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Embrace(TM) Hydrogel Embolic SystemP250003/S010 | Instylla, Inc. | PMA supplement | Oct 21, 2026 | FDA |
Embrace Hydrogel Embolic SystemP250003/S009 | Instylla, Inc. | PMA supplement | Sep 3, 2026 | FDA |
Embrace Hydrogel Embolic System (HES)P250003/S005 | Instylla, Inc. | PMA supplement | Apr 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Sirtex Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 300 Unicorn Park Dr., 2nd Floor ,, Woburn, MA, 01801
Sources and methodology
- Original FDA record: P220020/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


